# Phase III Study to Evaluate the Efficacy and Safety of AD-209

Study · id `cardio:ct-nct06348576` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06348576](<https://clinicaltrials.gov/study/NCT06348576>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06348576

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 280 participants.

## Technical summary

Registry record NCT06348576. Randomized; double masking; primary purpose treatment. Start 2024-05-20 (actual); primary completion 2025-02 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 280 participants (planned count; ClinicalTrials.gov record NCT06348576, source copy `cardio:ctgov-nct06348576-2024-05-21`, retrieved 2026-10-26)
- Started: 2024-05-20 (actual) (ClinicalTrials.gov record NCT06348576, source copy `cardio:ctgov-nct06348576-2024-05-21`, retrieved 2026-10-26)
- Primary completion: 2025-02 (anticipated) (ClinicalTrials.gov record NCT06348576, source copy `cardio:ctgov-nct06348576-2024-05-21`, retrieved 2026-10-26)
- Completion: 2025-02 (anticipated) (ClinicalTrials.gov record NCT06348576, source copy `cardio:ctgov-nct06348576-2024-05-21`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06348576, source copy `cardio:ctgov-nct06348576-2024-05-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06348576-2024-05-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase III Study to Evaluate the Efficacy and Safety of AD-209
- Condition: Hypertension,Essential
- Intervention (Drug): AD-209
- Intervention (Drug): AD-2091
- Intervention (Drug): AD-209 Placebo
- Intervention (Drug): AD-2091 Placebo
- Lead sponsor: Addpharma Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Addpharma Inc. (`cardio:org-addpharma-inc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT (`cardio:pubmed-41717679`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 017d18553e1c356e032df7341d6b5cc7720dd1edd6ef777915b7b1697148ef5e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
